BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 10981551)

  • 1. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
    Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
    Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration.
    Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
    Clin Sci (Lond); 2000 Oct; 99(4):331-41. PubMed ID: 10995600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
    Haddad G; Amiri F; Garcia R
    Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M; Chatellier G; Guyene TT; Ménard J
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade by intravenous losartan of AT1 angiotensin II receptors in rat brain, kidney and adrenals demonstrated by in vitro autoradiography.
    Zhuo J; Song K; Abdelrahman A; Mendelsohn FA
    Clin Exp Pharmacol Physiol; 1994 Jul; 21(7):557-67. PubMed ID: 7982288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats.
    Gohlke P; Von Kügelgen S; Jürgensen T; Kox T; Rascher W; Culman J; Unger T
    J Hypertens; 2002 May; 20(5):909-18. PubMed ID: 12011652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the angiotensin II Type 1 receptor by TCV-116: quantitation by in vitro autoradiography.
    Song K; Kanehara H; Takai S; Shiota N; Wada T; Inada Y; Miyazaki M
    Jpn J Pharmacol; 1999 Feb; 79(2):131-9. PubMed ID: 10202848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
    Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
    Belz GG; Breithaupt-Grögler K; Butzer R; Fuchs W; Hausdorf C; Mang C
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):336-41. PubMed ID: 11967820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of angiotensin II and losartan binding sites in glomeruli and mesangial cells.
    Chansel D; Bizet T; Vandermeersch S; Pham P; Levy B; Ardaillou R
    Am J Physiol; 1994 Mar; 266(3 Pt 2):F384-93. PubMed ID: 8160786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y; Naka T
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II receptor subtypes in renal cortex of rats and rhesus monkeys.
    Gibson RE; Thorpe HH; Cartwright ME; Frank JD; Schorn TW; Bunting PB; Siegl PK
    Am J Physiol; 1991 Sep; 261(3 Pt 2):F512-8. PubMed ID: 1653532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats.
    Nishiyama A; Yoshizumi M; Rahman M; Kobori H; Seth DM; Miyatake A; Zhang GX; Yao L; Hitomi H; Shokoji T; Kiyomoto H; Kimura S; Tamaki T; Kohno M; Abe Y
    Kidney Int; 2004 Mar; 65(3):972-81. PubMed ID: 14871417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptide angiotensin II receptor antagonists: in vivo inhibition of [125I-Sar1,Ile8]angiotensin II binding by losartan, EXP597 and L-159,282 in rats.
    Wong PC; Herblin WF; Barbera FA; Bernard R; Bozarth TA; Watson CA; Gibson RE
    Clin Exp Hypertens; 1996 Feb; 18(2):189-200. PubMed ID: 8869000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of candesartan on the renin system in conscious rats.
    Wagner C; Kurtz A
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S169-71. PubMed ID: 9892158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
    Paull JR; Widdop RE
    J Hypertens; 2001 Aug; 19(8):1393-402. PubMed ID: 11518847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.